ArticleFrontiers in nutrition2025
Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Triglyceride-cholesterol-body weight index and microvascular complications in Tibetan adults with type 2 diabetes: A cross-sectional study.The Journal of international medical research · 2026Article
- Associations of cumulative exposure and dynamic trajectories of the triglyceride-total cholesterol-body weight index with new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults: evidence from a nationwide prospective cohort study.Cardiovascular diabetology · 2026Article
- Association between the composite nutritional index TCBI and ISR.Frontiers in nutrition · 2026Article
- Baseline triglyceride-cholesterol-body weight index and risk of incident cardiovascular disease: evidence from the CHARLS and ELSA cohorts.Frontiers in nutrition · 2026Article
- Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-cholesterol-body weight index (TCBI), a novel parameter integrating serum triglycerides (TG), total cholesterol (TC), and body weight (BW), has not been comprehensively investigated in relation to metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to examine the association between TCBI and MASLD. Methods: This cross-sectional study used data from the NAGALA project in Japan, including 14,242 participants. TCBI was calculated using the formula: TG (mg/dL) × TC (mg/dL) × BW (kg)/1,000. Participants were stratified into quartiles based on natural log-transformed TCBI (TCBI-LN). The association between TCBI and MASLD was assessed using multiple logistic regression, restricted cubic splines (RCS), subgroup analyses, and receiver operating characteristic (ROC) curve analysis. Results: Among the 14,242 participants, the mean age was 43.53 ± 8.89 years, and 48.03% were female. In the fully adjusted model, each 1-unit increase in TCBI-LN was associated with a 1.69-fold increased risk of MASLD (OR = 2.69, 95% CI: 2.00-3.64, Conclusion: Triglyceride-cholesterol-body weight index showed a significant linear positive association with MASLD risk, particularly in individuals with abnormal BMI or normal WC. Moreover, TCBI demonstrated strong predictive accuracy for MASLD among individuals with normal BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.